Clinical Trials Browser

Bone Neoplasms, Sarcoma

NCT07340853 2026-03-10

CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

30 enrolled

Plasma cell

Multiple Myeloma

NCT06996249 2026-03-03

DuTOC

Recruiting

12,000 enrolled

Other solid neoplasmThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Mesothelioma, Thymus Neoplasms

NCT07169344 2026-01-28

PROSARC-1

Phase 2 Recruiting

110 enrolled

Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT06648278 2026-01-13

COUNTS2

Phase NA Recruiting

260 enrolled

Breast

Breast Neoplasms, Cardiovascular Diseases

NCT02296450 2025-12-19

Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments

Recruiting

1,025 enrolled

Tumor-Agnostic

Neoplasms

NCT06646471 2025-12-16

PROMETHEE

Phase 4 Recruiting

500 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06633224 2025-09-16

Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT

Recruiting

125 enrolled

GastrointestinalHead & Neck

Gastrointestinal Neoplasms, Head and Neck Neoplasms, Neoplasms

NCT07044076 2025-06-29

MenQOL

Recruiting

50 enrolled

CNS

Meningioma

NCT06907706 2025-04-02

Active Living After Cancer: Implementation Within Be Well Acres Homes

Phase NA Recruiting

164 enrolled

Fatigue, Neoplasms

Clinical Trials

QOLSarcoma

CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma

DuTOC

PROSARC-1

COUNTS2

Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments

PROMETHEE

Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT

MenQOL

Active Living After Cancer: Implementation Within Be Well Acres Homes